Dogwood Therapeutics
DWTX
22 hedge funds and large institutions have $5.4M invested in Dogwood Therapeutics in 2026 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.
96% more capital inflows, than outflows
Capital inflows: $620K | Capital outflows: $316K
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
38% more funds holding
Funds holding: 16 → 22 (+6)
0.37% more ownership
Funds ownership: 11.39% → 11.76% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$475K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68.5K |
| 3 |
HRT Financial
New York
|
+$56.4K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$7.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$314K |
| 2 |
BlackRock
New York
|
-$2.21K |
| 3 |
Barclays
London,
United Kingdom
|
-$274 |
DWTX Hedge Fund Activity: Q3 2026 in Review
22 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q3 2026, worth a combined $5.4M — down 12% from $6.17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DWTX positions and 0 closed out — a net gain of 6 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, adding an estimated $475K. The largest seller was Armistice Capital, cutting an estimated $314K.
- 22 institutional investors held Dogwood Therapeutics (DWTX) as of Q3 2026, up from 16 in Q2 2026.
- Funds reported $5.4M of Dogwood Therapeutics stock for Q3 2026, down 12% quarter-over-quarter.
- 6 funds opened new Dogwood Therapeutics positions in Q3 2026 and 0 closed out, a net change of +6 holders.
- The largest Dogwood Therapeutics buyer in Q3 2026 was Millennium Management, an estimated $475K added.
- The largest Dogwood Therapeutics seller in Q3 2026 was Armistice Capital, an estimated $314K sold.
Based on aggregated 13F filings for Q3 2026.